Mometasone Topical

Mometasone Topical is a prescription medication used for the treatment of inflammatory hyperkeratotic dermatosis. 

• Mometasone Topical live is available under the following different brand names: Elocon

Adult and pediatric dosage

Cream/ Lotion/ Ointment

• 0.1%

Inflammatory Hyperkeratotic Dermatosis

Adult dosage

• Apply cream, lotion, or ointment to the affected area every day

Pediatric dosage

• Aged below 2 years: Safety and efficacy not established
• Aged 2 years or older: As adults: apply cream, lotion, or ointment to the affected area every day
• Use beyond 3 weeks not studied

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

Common side effects of Mometasone Topical include:

• skin rash,
• itching,
• burning,
• redness,
• dryness,
• thinning or softening of the skin,
• skin rash or irritation around the mouth,
• swollen hair follicles,
• spider veins,
• numbness or tingling,
• changes in the color of treated skin,
• blisters,
• pimples,
• crusting of treated skin, or
• stretch marks.

Serious side effects of Mometasone Topical include:

• severe skin irritation;
• blurred vision, tunnel vision, eye pain, or seeing halos around lights; or
• high blood sugar--increased thirst, increased urination, dry mouth, fruity breath odor.

Rare side effects of Mometasone Topical include:

• none

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheartedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Mometasone Topical has severe interactions with the following drug:
  • mifepristone
• Mometasone Topical has serious interactions with the following drug:
  • aldesleukin
• Mometasone Topical has moderate interactions with the following drugs:
  • ceritinib
  • corticorelin
  • deferasirox
  • hyaluronidase
  • omacetaxine
• Mometasone Topical has minor interactions with no other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions or concerns.

Contraindications

• Hypersensitivity

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Mometasone Topical?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Mometasone Topical?”

Cautions

• Safety/efficacy in children's use for longer than 3 weeks is not established; pediatric patients may be more susceptible to systemic toxicity
• Do not use with occlusive dressings
• Not for acne, rosacea, perioral dermatitis, diaper dermatitis
• If concomitant skin infections are present or develop, use an appropriate antifungal or antibacterial agent; if a favorable response does not occur promptly, therapy should be discontinued until the infection has been adequately controlled
• If irritation develops, discontinue therapy and institute appropriate therapy; allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation; corroborate observation with appropriate diagnostic patch testing
• Use of topical corticosteroids may increase the risk of posterior subcapsular cataracts and glaucoma; cataracts and glaucoma reported in postmarketing experience with therapy; avoid contact with eyes; advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation
• Endocrine system effects
  • Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency; this may occur during treatment or after withdrawal of treatment
  • Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can be produced in some patients by systemic absorption of topical corticosteroids while on treatment
  • Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include use of high potency steroids, large treatment surface areas, prolonged use, use of the occlusive dressing, altered skin barrier, liver failure, and young age
  • Because of the potential for systemic absorption, the use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression; this may be done by using the adrenocorticotropic hormone (ACTH) stimulation test
  • If HPA axis suppression is documented, attempt to gradually withdraw the drug, reduce the frequency of application, or substitute a less potent corticosteroid; recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids; infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids
  • Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios

Pregnancy & Lactation

• Use with caution if benefits outweigh risks during pregnancy
• Lactation
  • Use caution